Speculation grows that Teva close to giant M&A deal - Business - Haaretz.com
Teva fined $519 million in U.S. for foreign bribes | News 7
Teva Might Have Been Better Off as a Smaller Company, new CEO Says | Ctech
Is A Fall Imminent For Teva Stock After Its Recent Rally?
AstraZeneca's Soriot reportedly moving to top job at Teva
Loss-Making Teva Pharmaceutical Industries Limited (NYSE:TEVA) Set To Breakeven - Simply Wall St News
Why did Teva Pharmaceutical shares drop today? Opioid litigation loss | Seeking Alpha
Is Teva Pharmaceutical a Safe Stock to Buy Now? | The Motley Fool
Investors wary of Teva-Mylan merger - MarketWatch
What really happened with Pascal Soriot's rumored move to Teva? | FiercePharma
Mylan plays monkey-in-the-middle of hostile takeover battles | Fortune
Who's Kare Schultz, (NYSE:TEVA) New CEO In Charge Of Teva? | Benzinga
The Difficulties of Cloning a CEO - Bloomberg
Teva slide could draw vultures but it won't be easy prey | The Times of Israel
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
Mylan Should Try Teva On for Size - WSJ
Mylan and Teva stocks rise on report about Amazon's pharmacy aims - MarketWatch
If AstraZeneca CEO Soriot does take Teva's helm, what comes next? Megamerger talk, maybe | FiercePharma
TEVA: Can Teva Pharmaceutical Stock Continue to Rebound in 2021?
Teva Makes $40.1B Bid for Generic-Drug Rival Mylan, Proving Rumors Right - TheStreet
Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going? - WSJ
Teva Is Said to Explore Takeover Offer for Mylan (Video) - Boston Business Journal
Speculation grows that Teva close to giant M&A deal - Business - Haaretz.com
Indian drugmakers among final few bidders for $1B Teva generics unit | FiercePharma
Teva slide could draw vultures but it won't be easy prey | The Times of Israel
